Hypothesis

Age‑related expansion of bile salt hydrolase (BSH)‑producing gut microbes deconjugates primary bile acids, lowering hepatic FXR activation and triggering a downstream decline in SIRT1‑mediated deacetylation of p53 and PPARα. This loss of SIRT1 activity promotes hepatocyte senescence, sustains a pro‑inflammatory secretome, and accelerates NAFLD‑to‑HCC progression.

Key Prediction

In aged humans, selective reduction of BSH‑positive taxa (e.g., Clostridium spp., Bacteroides spp.) will increase hepatic FXR‑SIRT1 signaling, decrease senescence‑associated biomarkers (p16^INK4a^, γH2AX, SASP cytokines), and lower histologic scores for steatosis, fibrosis, and neoplastic lesions compared with age‑matched controls.

Mechanistic Rationale

1. FXR directly induces SIRT1 transcription via an upstream enhancer element; reduced FXR activity in aging livers diminishes SIRT1 expression [4].
2. SIRT1 deacetylates p53, suppressing its pro‑senescence transcriptional program, and activates PPARα to enhance fatty‑acid oxidation, counteracting lipogenesis.
3. Consequently, BSH‑driven FXR loss creates a double hit: impaired bile‑acid‑feedback repression of CYP7A1/CYP8B1 (raising toxic bile‑acid load) and diminished SIRT1‑mediated senescence restraint.
4. Restoring FXR—either by inhibiting microbial BSH or delivering intestinal‑selective FXR agonists—should reactivate SIRT1, reset the NAD+/NADH balance, and attenuate senescence‑associated secretory phenotype (SASP).

Experimental Design

• Cohort: 120 participants aged 65‑80 with biopsy‑confirmed NAFLD (NAS ≥4) stratified by baseline fecal BSH activity (high vs low).
• Intervention: 12‑week course of a narrow‑spectrum antimicrobial or phage cocktail targeting Clostridium scindens and Bacteroides fragilis (major BSH carriers) versus placebo.
• Primary endpoints: change in hepatic FXR target gene expression (Shp, Fgf15 measured in circulating exosomes), hepatic SIRT1 protein levels (immunohistochemistry), and senescence markers (p16, γH2AX, IL‑6, IL‑8).
• Secondary endpoints: liver fat fraction (MRI‑PDFF), fibrosis (ELF test), and incidence of dysplastic nodules at 24 months.
• Fecal metagenomics and bile‑acid metabolomics will confirm target engagement (decreased secondary bile‑acid ratios, increased conjugated bile acids).

Falsifiability

If BSH reduction fails to raise hepatic FXR/SIRT1 activity or does not improve senescence biomarkers despite achieving expected shifts in the bile‑acid pool, the hypothesis is refuted. Conversely, a concordant improvement in FXR‑SIRT1 signaling coupled with reduced senescence would support the mechanistic link between microbial BSH, hepatic FXR signaling, and age‑related liver deterioration.

References [1] https://www.frontiersin.org/journals/microbiology/articles/10.3389/fmicb.2025.1513541/full [2] https://pmc.ncbi.nlm.nih.gov/articles/PMC11669848/ [3] https://pmc.ncbi.nlm.nih.gov/articles/PMC9938992/ [4] https://journals.physiology.org/doi/full/10.1152/ajpgi.00223.2019?doi=10.1152%2Fajpgi.00223.2019